CNBC’s Jim Cramer on Friday evaluated the stock of Abbott Laboratories, a healthcare company that’s been weighed down by ...

Following the robust Q3 performance, Piper Sandler raised ABT’s price target to $133 from $131, keeping an Overweight rating ...

Shares of Abbott Laboratories ABT slumped 0.79% to $116.80 Wednesday, on what proved to be an all-around great trading ...

They’re at the center of a legal battle with the makers of specialized formulas for preterm infants — north suburban-based ...

In the last three months, 15 analysts have published ratings on Abbott Laboratories (NYSE:ABT), offering a diverse range of perspectives from bullish to bearish. The table below summarizes their ...

On Tuesday, Abbott Laboratories (ABT) stock saw a modest uptick, ending the day at $117.73 which represents a slight increase of $0.08 or 0.07% from the prior close of $117.65. The stock opened at ...

Marie Thibault, an analyst from BTIG, reiterated the Buy rating on Abbott Laboratories (ABT – Research Report). The associated price ...

Abbott Laboratories (NYSE:ABT) rose 6% in after hours trading after a jury found the company and a Reckitt Benckiser ...

In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against the other pharma stocks. Healthcare takes the concept of 'defensive' further than almost any ...

We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...

On Monday, Barclays maintained an Overweight rating on Abbott Labs (NYSE:ABT) shares and increased the price target to $149 from $143. The adjustment follows a favorable verdict for Abbott in a ...

Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.